Flavin containing monooxygenase 3 exerts broad effects on glucose and lipid metabolism and atherosclerosis
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
We performed silencing and overexpression studies of flavin containing monooxygenase (FMO) 3 in hyperlipidemic mouse models to examine its effects on trimethylamine N-oxide (TMAO) levels and atherosclerosis. Knockdown of hepatic FMO3 in LDL receptor knockout mice using an antisense oligonucleotide resulted in decreased circulating TMAO levels and atherosclerosis. Surprisingly, we also observed significant decreases in hepatic lipids and in levels of plasma lipids, ketone bodies, glucose, and insulin. FMO3 overexpression in transgenic mice, on the other hand, increased hepatic and plasma lipids. Global gene expression analyses suggested that these effects of FMO3 on lipogenesis and gluconeogenesis may be mediated through the PPARα and Kruppel-like factor 15 pathways. In vivo and in vitro results were consistent with the concept that the effects were mediated directly by FMO3 rather than trimethylamine/TMAO; in particular, overexpression of FMO3 in the human hepatoma cell line, Hep3B, resulted in significantly increased glucose secretion and lipogenesis. Our results indicate a major role for FMO3 in modulating glucose and lipid homeostasis in vivo, and they suggest that pharmacologic inhibition of FMO3 to reduce TMAO levels would be confounded by metabolic interactions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nevertheless, there could be several problems with this approach as an accumulation of TMA leads to trimethylaminuria, which is characterized by fishy odor (similar to rotten fish) and induce inflammation [18,75,99].”
From Implication of Trimethylamine N-Oxide (TMAO) in Disease: Potential Biomarker or New Therapeutic Target (2018) · cites this paper as [99]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“important regulators in host lipid and sterol metabolism, as well as atherosclerosis development”
From Non-lethal Inhibition of Gut Microbial Trimethylamine Production for the Treatment of Atherosclerosis (2015) · cites this paper as Shih et al., 2015
In the citing paper
“FMO3 inhibition is also accompanied by several untoward side effects, including hepatic inflammation”
From Non-lethal Inhibition of Gut Microbial Trimethylamine Production for the Treatment of Atherosclerosis (2015) · cites this paper as Shih et al., 2015
In the citing paper
“host hepatic FMO3, the primary FMO responsible for TMAO production”
From Non-lethal Inhibition of Gut Microbial Trimethylamine Production for the Treatment of Atherosclerosis (2015) · cites this paper as Shih et al., 2015
In the citing paper
“suppression of the host enzyme, FMO3, through antisense oligonucleotide-based approach, results in reduction of both circulating TMAO levels and diet-enhanced atherosclerosis in animal models”
From Non-lethal Inhibition of Gut Microbial Trimethylamine Production for the Treatment of Atherosclerosis (2015) · cites this paper as Shih et al., 2015
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A SIMPLE METHOD FOR THE ISOLATION AND PURIFICATION OF TOTAL LIPIDES FROM ANIMAL TISSUES
Folch, J., Lees, M., & Stanley, G. H. S. (1957) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)64849-5 · Cited by 65,189
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease
Wang, Z., Klipfell, E., Bennett, B. J., Koeth, R., Levison, B. S., DuGar, B., Feldstein, A. E., Britt, E. B., Fu, X., Chung, Y.-M., et al. (2011) · Nature · doi:10.1038/nature09922 · Cited by 5,597
Self-citationInsulin signalling and the regulation of glucose and lipid metabolism
Saltiel, A. R., & Kahn, C. R. (2001) · Nature · doi:10.1038/414799a · Cited by 5,326
Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis
Koeth, R. A., Wang, Z., Levison, B. S., Buffa, J. A., Org, E., Sheehy, B. T., Britt, E. B., Fu, X., Wu, Y., Li, L., et al. (2013) · Nature Medicine · doi:10.1038/nm.3145 · Cited by 4,386
Self-citationIntestinal microbial metabolism of phosphatidylcholine and cardiovascular risk
Tang, W. H. W., Wang, Z., Levison, B. S., Koeth, R. A., Britt, E. B., Fu, X., Wu, Y., & Hazen, S. L. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1109400 · Cited by 3,400
Self-citationRepa, J. J., Liang, G., Ou, J., Bashmakov, Y., Lobaccaro, J.-M. A., Shimomura, I., Shan, B., Brown, M. S., Goldstein, J. L., & Mangelsdorf, D. J. (2000) · Genes & Development · doi:10.1101/gad.844900 · Cited by 1,692
SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth
Porstmann, T., Santos, C. R., Griffiths, B., Cully, M., Wu, M., Leevers, S., Griffiths, J. R., Chung, Y.-L., & Schulze, A. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.07.007 · Cited by 1,413
Delerive, P., De Bosscher, K., Besnard, S., Vanden Berghe, W., Peters, J. M., Gonzalez, F. J., Fruchart, J.-C., Tedgui, A., Haegeman, G., & Staels, B. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.45.32048 · Cited by 1,089
Bennett, B. J., Vallim, T. Q. D. A., Wang, Z., Shih, D. M., Meng, Y., Gregory, J., Allayee, H., Lee, R., Graham, M., Crooke, R., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2012.12.011 · Cited by 1,070
Self-citationLi, S., Brown, M. S., & Goldstein, J. L. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914798107 · Cited by 733
Cited by
Items 301–342 of 342
Novel Mediators of Diabetes-Associated Cardiovascular Disease
Gearing, M. E. (2017) · Digital Access to Scholarship at Harvard (DASH) (Harvard University) · Cited by 1
Gut Microbiota and Risk for Atherosclerosis: Current Understanding of the Mechanisms
Dutta, B., Biswas, C., Arya, R. K., & Rahaman, S. O. (2020) · Springer eBooks · doi:10.1007/978-3-030-47384-6_8 · Cited by 1
Nutraceuticals Supporting Heart Function in Heart Failure
Cicero, A. F. G., & Colletti, A. (2021) · Contemporary cardiology · doi:10.1007/978-3-030-62632-7_11
Gut-Hepatic Relationship: From Disorders of the Gut Microbiota to Hepatocellular Carcinoma
Murkamilov, I. T. (2021) · American Journal of Biomedical Science & Research · doi:10.34297/ajbsr.2021.11.001681
“This can lead to an increase in the accumulation of hepatic triglycerides, as TMAO inhibits key enzymes and limits the enterohepatic circulation of bile acids [70-72].”
BackgroundGut Microbial Dysbiosis and Cardiovascular Diseases
Gasmi, A., Noor, S., Piscopo, S., & Berthouze, S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819265-8.00050-4
Gut microbiota and their effects on atherosclerosis, platelet function, and hypertension
Duttaroy, A. K. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822405-2.00022-0 · Cited by 1
How Oxidative Systems Metabolise Substrates
Coleman, M. D. (2020) · Wiley eBooks · doi:10.1002/9781119658016.ch3
Shyshkan-Shyshova, К. О., & Zinych, О. В. (2022) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.18.4.2022.1177 · Cited by 2
Breath Analysis in Children with Ketogenic Glycogen Storage Diseases
Kabbany, M. N., Selvakumar, P. K. C., Han, X., Wang, X., Grove, D., Tonelli, A. R., Dweik, R. A., Minarich, L. A., Radhakrishnan, K. R., & Alkhouri, N. (2022) · Livers · doi:10.3390/livers2040025
Ouyang, L., Zhang, B., Huang, H., Wang, J., Luo, J., Liu, H., & Chang, X.-R. (2023) · Journal of Acupuncture and Tuina Science · doi:10.1007/s11726-023-1353-9
“Down-regulation of FMO3 reduces TMAO level, but inhibition of FMO3 prevents fishy TMA from being converted to TMAO and excreted via urine and sweat, resulting in fishy odor syndrome[20].”
BackgroundGut Microbiota and Cardiovascular Disease
Negm, S. H. (2023) · Wiley eBooks · doi:10.1002/9781119904786.ch9 · Cited by 3
Li, X., Song, J., Shi, X., Huang, M., Liu, L., Yi, G., Yang, N., Xu, G., & Zheng, J. (2022) · Figshare · doi:10.6084/m9.figshare.21564282
Li, X., Song, J., Shi, X., Huang, M., Liu, L., Yi, G., Yang, N., Xu, G., & Zheng, J. (2022) · Figshare · doi:10.6084/m9.figshare.21564312
Li, X., Song, J., Shi, X., Huang, M., Liu, L., Yi, G., Yang, N., Xu, G., & Zheng, J. (2022) · Figshare · doi:10.6084/m9.figshare.21564285
Li, X., Song, J., Shi, X., Huang, M., Liu, L., Yi, G., Yang, N., Xu, G., & Zheng, J. (2022) · Figshare · doi:10.6084/m9.figshare.21564309
Li, X., Song, J., Shi, X., Huang, M., Liu, L., Yi, G., Yang, N., Xu, G., & Zheng, J. (2022) · Figshare · doi:10.6084/m9.figshare.21564279
李, 蓉. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.1441200
Doering, K. R. S., Taubert, S., Ermakova, G., Sabatino, B., Cheng, R., Kugathasan, L., & DeBoer, Z. (2025) · doi:10.59368/agingbio.20250040 · Cited by 1
TMAO promotes disorders of lipid metabolism in psoriasis.
Li, R., Hu, B., Mao, M., Chen, W., & Zhu, W. (2025) · PubMed Central · doi:10.11817/j.issn.1672-7347.2024.240663
“Notably, pharmacological inhibition of FMO3 to attenuate circulating TMAO concentrations has been demonstrated to exert beneficial effects in maintaining metabolic homeostasis [27] .”
Mao, Y., Gu, N., Ma, X., Wang, Y., Yu, N., Lu, D., Tong, L., Guo, X., Zhang, J., Gao, Y., et al. (2025) · International Journal of Endocrinology · doi:10.1155/ije/1020054
“FMO3 can reduce glucose tolerance, promote lipid metabolism disorders and atherosclerosis formation, and inhibit energy metabolism, thus promoting the occurrence of obesity, and promote the occurrence of infammation and platelet aggregation [21].”
Li, X., Song, J., Shi, X., Huang, M., Liu, L., Yi, G., Yang, N., Xu, G., & Zheng, J. (2022) · Figshare · doi:10.6084/m9.figshare.21564303
Li, X., Song, J., Shi, X., Huang, M., Liu, L., Yi, G., Yang, N., Xu, G., & Zheng, J. (2022) · Figshare · doi:10.6084/m9.figshare.21564300
Yam, P., VerHague, M., Albright, J., Gertz, E., de Villena, F. P., & Bennett, B. J. (2022) · Figshare · doi:10.6084/m9.figshare.20461935
Self-citationLi, X., Song, J., Shi, X., Huang, M., Liu, L., Yi, G., Yang, N., Xu, G., & Zheng, J. (2022) · Figshare · doi:10.6084/m9.figshare.21564291
Li, X., Song, J., Shi, X., Huang, M., Liu, L., Yi, G., Yang, N., Xu, G., & Zheng, J. (2022) · Figshare · doi:10.6084/m9.figshare.21564297
Li, X., Song, J., Shi, X., Huang, M., Liu, L., Yi, G., Yang, N., Xu, G., & Zheng, J. (2022) · Figshare · doi:10.6084/m9.figshare.21564294
Li, X., Song, J., Shi, X., Huang, M., Liu, L., Yi, G., Yang, N., Xu, G., & Zheng, J. (2022) · Figshare · doi:10.6084/m9.figshare.21564306
Li, X., Song, J., Shi, X., Huang, M., Liu, L., Yi, G., Yang, N., Xu, G., & Zheng, J. (2022) · Figshare · doi:10.6084/m9.figshare.21564288
Impact of Gut Microbiota on Platelet Function
Duttaroy, A. K. (2025) · Springer eBooks · doi:10.1007/978-3-031-96352-0_9
Gupta, H., Kumari, P., & Singh, R. P. (2026) · Glycoscience & Therapy · doi:10.1016/j.glycos.2026.100029
Vasudevan, D. (2026) · World Journal of Diabetes · doi:10.4239/wjd.v17.i3.113843
Gut Microbiota: Cardiovascular Disease Prevention and Targeted Therapies
Loguercio, M., Giamundo, D. M., Giglio, A., Buda, E., Ambrosetti, M., & Perone, F. (2026) · Biomedicines · doi:10.3390/biomedicines14061210
“Reducing FMO3 expression has been shown to influence metabolic health, regulate cholesterol and glucose metabolism, reduce atherosclerosis, and improve metabolic profiles in mouse models [69].”
Moagi, M. G., Beke, L., Méhes, G., Kecskeméti, G., Szabó, Z., Turiák, L., & Csősz, É. (2026) · Proteomes · doi:10.3390/proteomes14020030
“At the protein level, multiple enzymes involved in the synthesis and quality of carbohydrates [41], lipid biosynthesis [42,43], and protein production [44] were interconnected, which supports a coordinated upregulation of biosynthetic pathways.”
Park, Y. J., Yu, J., Kang, J. H., Park, S. J., Jeong, S., Lee, G., Shin, H.-Y., & Park, S. M. (2026) · Cancer Epidemiology · doi:10.1016/j.canep.2026.103152
Elevated plasma TMAO levels associated with all-cause mortality in CAD patients in South China
Zhang, H., Peng, Y., Lu, X.-Y., Li, Y. Y., Li, W., Hu, Y., Li, W., & Chen, B.-L. (2026) · BMC Cardiovascular Disorders · doi:10.1186/s12872-026-06214-9
“Animal models suggest that TMAO may affect glucose metabolism and promote diabetes [24–26].”
Tang, J., Zaretsky, J. A., Labajo, J. D., Shaqo, A., Dakroub, H., Shelp, G. V., Poole, E. M., Burns, S. E., & Cho, C. E. (2026) · iScience · doi:10.1016/j.isci.2026.116720
Wang, B., Yang, Y., Ho, Y. M., Lin, H., Yuan, J., Long, K., Cheng, K. K. Y., & Li, X. (2026) · Nature Communications · doi:10.1038/s41467-026-76075-5
“%) in rodents 8,29,30 .”
Hepatic FMO3 Downregulation Contributes to the Metabolic Benefits of Vertical Sleeve Gastrectomy
Yan, H., Cao, C., Tan, X., Huang, X., Liu, Y., Chu, Y., He, M., Yao, Q., Hua, R., & Shao, Y. (2026) · Obesity · doi:10.1002/oby.70281
Altahrawi, A. Y., Sofi, F., Kanjwal, Z., & Shah, Z. A. (2026) · Cells · doi:10.3390/cells15201845
“Previous studies have demonstrated that increased hepatic FMO3 expression increased circulating TMAO levels, whereas suppressing FMO3 was associated with decreased TMAO production [17,18].”
Microbiota-derived toxicants targeting mitochondria
Bahitham, W., Almuaiqly, G., Abumelha, W., Ghazzawi, R., Ghazzawi, G., Alsahafi, R., Sanai, F. M., Sergi, C. M., & Rosado, A. S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-45078-5.00023-3
Metadata
- Authors
- Shih, D. M., Wang, Z., Lee, R., Meng, Y., Che, N., Charugundla, S., Qi, H., Wu, J., Pan, C., Brown, J. M., Vallim, T., Bennett, B. J., Graham, M., Hazen, S. L., & Lusis, A. J.
- Affiliations
- University of California, Los Angeles (US)
- Cleveland Clinic (US)
- Ionis Pharmaceuticals (United States) (US)
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Lusis, Aldons J.
- ORCID
- Venue
- Journal of Lipid Research
- Publisher
- Elsevier BV
- Published
- 2015-01
- Volume
- 56
- Issue
- 1
- Pages
- 22-37
- ISSN
- 0022-2275 (ISSN-L)
- PMC
- PMC4274068
- OpenAlex
- W2163604084
- Cited by
- 335
- References
- 46
- Citations by year
- 2026: 17 · 2025: 19 · 2024: 18 · 2023: 20 · 2022: 43 · 2021: 36 · 2020: 44 · 2019: 33 · 2018: 28 · 2017: 28 · 2016: 33 · 2015: 16
- FWCI
- 29.47
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 2088 d)
- Locations
- Journal of Lipid Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- UNC Libraries
- Funders
- National Institutes of Health (HL‐28481, HL30568, HL113452)
- National Heart, Lung, and Blood Institute (HL3 0568, HL28481, P01HL030568, HL113452, P20HL113452, P01HL028481)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
- Keywords
- FMO3, trimethylamine N-oxide, atherosclerosis, glucose metabolism, lipid metabolism, hepatic lipogenesis, gluconeogenesis, PPARα, KLF15, hyperlipidemia, LDL receptor knockout mice, hepatic lipid accumulation, insulin, ketone bodies
- MeSH terms
- Animals, Bile Acids and Salts, DNA-Binding Proteins, Feces, Female, Glucose, Homeostasis, Humans, Insulin, Intestinal Mucosa, Lipoproteins, Liver, Methylamines, Oxygenases, Receptors, LDL, Transcription Factors, Gene Expression Regulation, Enzymologic, Cell Line, Tumor, PPAR alpha, Lipogenesis, Atherosclerosis, Lipid Metabolism, Mice, Kruppel-Like Transcription Factors, Gene Knockdown Techniques, Gene Knockout Techniques, Diet, Western
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.